Boston Scientific Corporation, a leading global medical technology company, stated it got approval from the US FDA for the Farawave NAV Ablation Catheter and FDA 510(k) clearance for the Faraview Software, both used in treating paroxysmal atrial...
Indian companies supply 40% of the world's generic medicines, showcasing India's important role in global healthcare. Dr. Jitendra Kumar, Managing Director of BIRAC, stated that the biotechnology industry in the country is experiencing impressive...
TuHURA Biosciences, a company in phase 3 of registering immune-oncology, is creating new technologies to tackle resistance to cancer immunotherapy. They have finished the merger with Kintara Therapeutics, Inc. and are now called TuHURA Biosciences...
Sanofi and Orano Med, which is a part of the Orano Group and specializes in targeted alphatherapies for cancer treatment, have agreed to collaborate in order to advance the development of advanced radioligand treatments for rare cancers. Sanofi...
Lindy Biosciences, a protein therapeutic formulations firm, has announced a partnership with Novartis Pharmaceuticals to focus more on evolving drugs from Novartis to subcutaneous injections by using their micro classification suspension...
USV Pvt. Ltd. has launched OnArni, a combination of Sacubitril and Valsartan, for treating heart failure, available at an affordable price of Rs. $8 is the cost for each tablet of 50mg. This affordable solution helps tackle the increasing...
Arbele, a leading innovator in biopharmaceutical and biotechnology focused on targeting cadherin-17 (CDH17), has announced a strategic collaboration in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of...
ModeX Therapeutics Inc, a biotechnology company under OPKO Health, Inc., reveals that it has received $35 million more in funding from BARDA, a branch of HHS responsible for Strategic Preparedness and Response in the US. The firm will start...
AstraZeneca, a British company, has partnered exclusively with CSPC Pharmaceutical Group from China to further develop a new small molecule disruptor for Lipoprotein (a) (Lp(a)), which could provide extra benefits for dyslipidemia patients...
Recipharm, a top global pharmaceutical CDMO, is enhancing its pharmaceutical development abilities by making strategic investments and incorporating advanced technologies. This investment enhances its offerings for both early and late-stage...
, CDSCO.jpg)
